2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1829

Ability of Inflammatory and Regulatory Soluble Mediators to Forecast Impending Clinical Disease Flare and Inform a Refined Lupus Flare Prediction Index in a Confirmatory Cohort of SLE Patients
Abstract Number: 1830

Short- and Long-term Morbidity and Mortality Outcomes of African American Patients with Systemic Sclerosis-Related Interstitial Lung Disease
Abstract Number: 1831

Subtypes of Scleroderma Lung Involvement Associated with Burden of Disease and Outcomes
Abstract Number: 1832

Reliability of Traditional Cardiovascular Risk Calculators in Predicting Risk of Cardiovascular Disease in Systemic Sclerosis
Abstract Number: 1833

Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease by Use of Mycophenolate at Baseline: Subgroup Analysis of the SENSCIS Trial
Abstract Number: 1834

Serum Interferon Chemokine Score Predicts Better Response to Immunosuppression in Systemic Sclerosis Related Interstitial Lung Disease
Abstract Number: 1835

Frequency and Predictors of Meaningful Decline in Forced Vital Capacity During Follow up оf a Large Cohort of Systemic Sclerosis Associated Pulmonary Fibrosis Patients
Abstract Number: 1836

Clinical Outcomes of Patients with Giant Cell Arteritis with Polymyalgia Symptoms Only vs Cranial Symptoms Only Treated with Tocilizumab or Placebo in a Randomized Clinical Trial
Abstract Number: 1837

Ustekinumab for the Treatment of Giant Cell Arteritis
Abstract Number: 1838

Time to Flare in Patients with New-Onset versus Relapsing Giant Cell Arteritis Treated with Tocilizumab or Placebo Plus Prednisone Tapering: 3-Year Results from a Randomized Controlled Phase 3 Trial
Abstract Number: 1839

Different Patterns and Specific Outcomes of Large-Vessel Involvements in Giant Cell Arteritis
Abstract Number: 1840

Risk Factors for Treatment Failure in Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone versus Prednisone Alone
Abstract Number: 1841

Resolution of Vascular Inflammation in Patients with Giant Cell Arteritis Receiving Glucocorticoids, Methotrexate or Tocilizumab Treatment: Data from the Italian/German RIGA Study
Abstract Number: 1842

Patients and Relatives Coping with Inflammatory Arthritis: Impact of Communication, Social Support and Relatives Burden on Patients Perceived Health
Abstract Number: 1843

Predictors of Mortality Among Black Women with Systemic Lupus Erythematosus: The Black Women’s Experiences Living with Lupus (BeWELL) Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].